Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Liquidia Corporation before investing.

In this article, we go over a few key elements for understanding Liquidia Corporation’s stock price such as:

• Liquidia Corporation’s current stock price and volume
• Why Liquidia Corporation’s stock price changed recently
• Upgrades and downgrades for LQDA from analysts
• LQDA’s stock price momentum as measured by its relative strength

About Liquidia Corporation (LQDA)

Before we jump into Liquidia Corporation’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company’s lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

Want to learn more about Liquidia Corporation’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Liquidia Corporation.

Liquidia Corporation’s Stock Price as of Market Close

As of May 21, 2026, 12:32 PM, CST, Liquidia Corporation’s stock price was $61.080.

Liquidia Corporation is down 1.12% from its previous closing price of $61.770.

During the last market session, Liquidia Corporation’s stock traded between $59.950 and $61.830. Currently, there are approximately 88.01 million shares outstanding for Liquidia Corporation.

Liquidia Corporation’s price-earnings (P/E) ratio is currently at 253.2, which is high compared to the Pharmaceuticals industry median of 19.7. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Liquidia Corporation Stock Price History

Liquidia Corporation’s (LQDA) price is currently up 55.78% so far this month.

During the month of May, Liquidia Corporation’s stock price has reached a high of $62.170 and a low of $37.450.

Over the last year, Liquidia Corporation has hit prices as high as $62.170 and as low as $11.850. Year to date, Liquidia Corporation’s stock is up 77.09%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Liquidia Corporation Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 20, 2026, there was 1 analyst who downgraded Liquidia Corporation’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Liquidia Corporation’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Liquidia Corporation’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Liquidia Corporation’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Liquidia Corporation (LQDA) by visiting AAII Stock Evaluator.

Relative Price Strength of Liquidia Corporation

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 20, 2026, Liquidia Corporation has a weighted four-quarter relative price strength of 40.90%, which translates to a Momentum Score of 96 and is considered to be Very Strong.

Want to learn more about how Liquidia Corporation is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Liquidia Corporation Stock Price: Bottom Line

As of May 21, 2026, Liquidia Corporation’s stock price is $61.080, which is down 1.12% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Liquidia Corporation stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.